Differentiated product
Deferasirox
Oral suspension · Transfusional haemosiderosis (2 years+)
Product data
- Dosage form
- Oral suspension
- Dosage-form group
- Oral liquid
- Therapeutic area
- Transfusional haemosiderosis (2 years+)
- Reference product
- Tablet for oral suspension 125, 250, 500 mg
- Status
- 6-month stability completed
- Development stage
- 3 of 5 · Stability data
- Portfolio
- Differentiated product
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23